A Randomized, Open-Label, 6-Period Cross-Over Study to Investigate the Dose Response of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects with Type 1 Diabetes Mellitus (T1DM)
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Insulin (Primary) ; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Dance Biopharm
- 11 Nov 2019 According to an Aerami Therapeutics media release, findings from two clinical studies (SAMBA-03 and SAMBA-04) will be presented at the 19th Diabetes Technology Meeting taking place on November 14-16, 2019
- 04 Jun 2019 According to a Dance Biopharm media release, data from this trial will be presented at the 79th Scientific Sessions of the American Diabetes Association (#ADA2019).
- 18 May 2019 Status changed from recruiting to completed.